Astrana Health, Inc.ASTHNASDAQ
LOADING
|||
ASTH Revenue Growth (YoY Quarterly)•+99.71%
SAPRO
Growth Metrics
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +37.49% | +88.43% | +53.43% | +34.66% | +99.71% |
| Gross Profit Growth | +0.95% | +61.66% | +3.58% | +18.10% | +11.03% |
| EBITDA Growth | -6.87% | +27.13% | -35.23% | -35.08% | -9.20% |
| Operating Income Growth | -27.27% | +0.00% | -31.71% | -32.35% | -32.42% |
| Net Income Growth | -27.04% | -156.26% | -54.89% | -50.85% | -97.68% |
| EPS Growth | -27.66% | -153.85% | -54.84% | -52.50% | -197.06% |
| EPS Diluted Growth | -29.79% | -153.85% | -54.84% | -52.50% | -200.00% |
| Weighted Average Shares Growth | +2.45% | +0.86% | +1.29% | +3.30% | +3.15% |
| Weighted Average Shares Diluted Growth | +2.78% | +0.86% | +2.08% | +3.11% | +2.59% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +120.58% | -156.73% | +178.18% | +292.01% | -70.70% |
| Free Cash Flow Growth | +180.41% | -210.10% | +141.74% | +339.66% | -76.63% |
| Receivables Growth | +22.03% | +119.83% | +78.38% | +62.17% | +75.57% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +19.76% | +45.16% | +8.56% | +15.16% | +74.05% |
| Book Value per Share Growth | +15.84% | +15.05% | +12.61% | +9.15% | +6.71% |
| Debt Growth | +101.97% | +46.98% | +4.10% | -5.86% | +128.50% |
| R&D Expense Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| SG&A Expenses Growth | +28.54% | +9.71% | +13.36% | +41.09% | +199.21% |
1 / 3